303957-69-9
Chemical Structure
Reutericyclin
Synonym(s): Reutericycline
- CAS No.: 303957-69-9
- Formula:C20H31NO4
- Molecular Weight:349.46
IUPAC Name: (R,E)-4-acetyl-1-(dec-2-enoyl)-5-hydroxy-2-isobutyl-1,2-dihydro-3H-pyrrol-3-one
InChIKey: QHXAUDQIMHYILR-LPQFERQCSA-N
SMILES: O=C1[C@@H](CC(C)C)N(C(/C=C/CCCCCCC)=O)C(O)=C1C(C)=O
Biological Activity: Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Reutericyclin | 98.08% | Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Hurdle JG, et al. Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations. J Antimicrob Chemother. 2011;66(8):1773-1776. [Content Brief]
- [2]. Aboulalazm F A, et al. Reutericyclin, a specialized metabolite of Limosilactobacillus reuteri, mitigates risperidone-induced weight gain in mice[J]. Gut Microbes, 2025, 17(1): 2477819.
- [3]. Hurdle JG, et al. Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections. Antimicrob Agents Chemother. 2009;53(9):4028-4031. [Content Brief]
- [4]. Hofstetter S, et al. Effects of nisin and reutericyclin on resistance of endospores of Clostridium spp. to heat and high pressure. Food Microbiol. 2013;34(1):46-51. [Content Brief]
Keywords
